Status:
TERMINATED
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
Lead Sponsor:
Exelixis
Conditions:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocyti...
Eligibility Criteria
Inclusion
- Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Prior treatment with at least 2 systemic chemotherapy regimens for CLL
- Life expectancy of \>3 months
- Adequate liver and kidney function
- Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL
- Willing to use accepted method of contraception during the course of the study
- Negative pregnancy test (females)
- Written informed consent
Exclusion
- Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- Investigational drug within 30 days of the start of treatment
- Uncontrolled intercurrent illness such as infection or cardiovascular disease
- Pregnant or breastfeeding women
- Subjects known to be HIV positive
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00234481
Last Update
June 4 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope National Cancer Center
Duarte, California, United States, 91010
2
UCSD Moores Cancer Center
San Diego, California, United States, 92093
3
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030